Status: Recruiting
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
Participants needed: 45
Trial details
Phase: Phase 1Age: 1+Biological sex: AllType: InterventionalSponsor: Stephan Grupp MD PhDUpdated: Dec 29, 2025Locations: 1
Eligibility criteria
Patients must be ≥ 1 year of age [+12]
Patients with active hepatitis B or active hepatitis C. [+35]